EndoDNA has launched BIOS, a patented clinical decision-support platform designed to help licensed healthcare practitioners translate genetic and biological data into structured clinical insight.
BIOS replaces the company’s legacy interpretation engine, myDNALive. The platform is aimed at functional, integrative, regenerative, hormone-optimisation and longevity practitioners who need a more continuous view of patient biology rather than static genetic reports.
This is relevant because clinicians increasingly have access to genomic, biomarker and lifestyle data, but still face challenges turning that information into practical care decisions. Precision medicine adoption often depends less on data generation and more on interpretation, workflow fit and clinical usability.
BIOS brings together genomics, biomarkers, lifestyle inputs, symptoms and ongoing patient data through a HIPAA-compliant dashboard. It allows licensed practitioners to order DNA tests, generate specialised reports from genotype files, integrate lab data, assess pharmacogenomic interactions and query genomic information using natural-language search.
The platform is built around biological pathways rather than isolated single-nucleotide polymorphism interpretation. EndoDNA said BIOS analyses approximately 1 million validated variants across 21 pathway systems, with 214 pathways curated for real-time clinical decision support.
The system uses four connected memory networks: population-level genomic evidence, aggregated practitioner case history, practitioner notes and patient-reported outcomes or biomarker trends. This differentiates the platform from single-report genetic interpretation tools by supporting longitudinal clinical reasoning.
EndoDNA said it has served more than 10,000 patients across more than nine countries through CAP/CLIA-accredited laboratory partners. The company also reports 99.6 per cent genotyping accuracy using Illumina next-generation sequencing.
The development reflects the next phase of precision medicine tools, where platforms must move beyond genetic reports and support ongoing clinical interpretation. Long-term scalability will depend on whether systems like BIOS can make complex biological data more actionable without creating overreliance on algorithmic outputs.
